Business Context and Reporting Period
This Form 8-K was filed by Vir Biotechnology, Inc. on March 9, 2020, reporting an event that occurred on March 3, 2020. The filing details a material amendment to an existing Collaboration and License Agreement with Alnylam Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on the terms of a new strategic agreement.
Material Changes and Agreement Terms
Vir Biotechnology and Alnylam Pharmaceuticals expanded their collaboration to include the development and commercialization of RNAi therapeutics targeting SARS-CoV-2 (COVID-19) and potentially other coronaviruses. Key financial terms include:
- Pre-clinical Costs: Each party bears its own pre-clinical development costs. Costs for manufacturing non-GMP drug product prior to the first investigational new drug application are shared equally.
- Development Responsibility: If Vir exercises its option to progress candidates, it assumes sole responsibility for development, manufacturing, and commercialization expenses.
- Alnylam Opt-in: Alnylam retains the right to opt-in during a specified period to share equally in profits and losses for development and commercialization.
- Milestone Payments: If Vir exercises its option and Alnylam does not opt-in, Vir must pay Alnylam up to $15.0 million in aggregate for specified development milestones.
- Sales Milestones and Royalties: Vir must pay specified sales milestones and tiered royalties on annual net sales. Royalties for sales to governmental authorities or for public health purposes are reduced to low single-digits plus a pass-through of third-party royalties.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or general outlook statements. The primary contingency is the successful development of COV Products and Vir's decision to exercise its option to progress the program. The agreement remains subject to the terms of the full Amendment text, which is to be filed as an exhibit in a subsequent filing.
Investor Verification Checklist
- Verify the specific timeline for the "specified period" during which Alnylam may opt-in to share profits and losses.
- Confirm the exact definition of "specified development milestones" triggering the up to $15.0 million payment.
- Review the subsequent filing containing the full text of the Amendment for detailed royalty tiers and sales milestone thresholds.
- Assess the impact of the "low single-digits" royalty rate on potential government sales versus commercial sales.